PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease [0.03%]
PBT2减少聚谷氨酰胺聚集模型秀丽隐杆线虫的毒性并延长寿命、减轻亨廷顿舞蹈病R6/2小鼠模型纹状体萎缩并改善运动行为
Robert A Cherny,Scott Ayton,David I Finkelstein et al.
Robert A Cherny et al.
Background: There is evidence that interaction with biologically important metals, particularly copper and iron, contributes to the pathological aggregation and toxicity of the mutant huntingtin protein in HD. PBT2 is a n...
Home or Residential Care? The Role of Behavioral and Psychosocial Factors in Determining Discharge Outcomes for Inpatients with Huntington's Disease [0.03%]
回家还是住宅护理？行为和心理社会因素在决定亨廷顿病住院患者出院结果中的作用是什么？
Fiona Fisher,Sophie Andrews,Andrew Churchyard et al.
Fiona Fisher et al.
Background: The progressive nature of Huntington's disease (HD) means that families often struggle to cope with increasing care needs of their affected family member. As a result, individuals with HD are likely to be at r...
Practice, progress and future directions for physical therapies in Huntingtons disease [0.03%]
亨廷顿病物理治疗的实践、进展和未来方向
Monica Busse,Hanan Khalil,Simon Brooks et al.
Monica Busse et al.
Physical therapies and exercise may have potential as a disease modifying agent in Huntington's disease (HD) and in recent years, there have been several small scale feasibility studies that have shown benefit as a result of physical interv...
Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms [0.03%]
亨廷顿舞蹈病的认知障碍：人类、小鼠模型和分子机制研究
Albert Giralt,Ana Saavedra,Jordi Alberch et al.
Albert Giralt et al.
Huntington's disease (HD) is an autosomal dominant progressive neurodegenerative disorder due to an expanded CAG/polyglutamine repeat in the coding region of the huntingtin (htt) gene that causes the preferential degeneration of striatal ne...
New Perspectives on the Neuropathology in Huntington's Disease in the Human Brain and its Relation to Symptom Variation [0.03%]
亨廷顿舞蹈病人类脑组织的新神经病理学观点及其与症状变异性的关系
Henry J Waldvogel,Eric H Kim,Doris C V Thu et al.
Henry J Waldvogel et al.
We review recent investigations regarding the relationship between selective neurodegeneration in the human brain and the variability in symptom profiles in Huntington's disease. Huntington's disease is a genetic neurodegenerative disorder ...
Eugenics, Heredity, and Huntington's Disease: A Brief Historical Perspective [0.03%]
优生学、遗传与亨廷顿病：简要历史视角
A Wexler
A Wexler
Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease [0.03%]
渐冻症基因携带者和早期亨廷顿病患者的视觉工作记忆障碍
Eve M Dumas,Miranda J Say,Rebecca Jones et al.
Eve M Dumas et al.
Working memory deficits have been found in Huntington's disease (HD) and in a small group of premanifest (PreHD) gene-carriers. However, the nature and extent of these deficits are unknown. In a large cross-sectional study, we aimed to dete...
Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10 [0.03%]
辅酶Q10治疗的亨廷顿病和健康对照者血浆中8-羟基-2'-脱氧鸟苷水平的研究
K M Biglan,E R Dorsey,R V V Evans et al.
K M Biglan et al.
We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg...
Clinical Trial
Journal of Huntington's disease. 2012;1(1):65-9. DOI:10.3233/JHD-2012-120007 2012
Laura E I A&#x;Campo,Noëlle G A Spliethoff-Kamminga,Raymund A C Roos
Laura E I A&#x;Campo
The goal of the Patient Education Program for Huntington's disease is to improve quality of life for patients and caregivers, to educate and train them in order to develop coping strategies to deal with psychosocial stressors. The program w...
Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease [0.03%]
奥氮平诱导的亨廷顿病患者的神经综合征
Jose Luis López-Sendón Moreno,Jose María Palau Fayos,Alberto Díaz de Santiago et al.
Jose Luis López-Sendón Moreno et al.